AI Financial Intelligence
Professional analysis of central bank decisions

Markets

News
Forex
Stocks
Crypto
Gold
Commodities
Indices
ETFs

Analysis

Fed
ECB
COT
Economic Calendar

Learn

Service Guide
MCP Server
Oil

Company

About
Contact
Data Methodology
AI Disclosure
Pricing
Enterprise
Terms
Privacy
Security
WhatsApp

Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookiesPrivacy Policy

AI Financial Intelligence
Professional analysis of central bank decisions

Markets

News
Forex
Stocks
Crypto
Gold
Commodities
Indices
ETFs

Analysis

Fed
ECB
COT
Economic Calendar

Learn

Service Guide
MCP Server
Oil

Company

About
Contact
Data Methodology
AI Disclosure
Pricing
Enterprise
Terms
Privacy
Security
WhatsApp

Status data is currently unavailable

The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

BreakingStocks

Merck Hikes Full-Year Profit Outlook After Q3 Earnings Beat

First Detected: Oct 29, 2026, 10:38 AM

Last Update: 26 minutes ago

1 update

Event Summary

Merck exceeded third-quarter profit and revenue estimates, leading the company to raise its full-year adjusted profit outlook. This growth was primarily driven by robust sales of its cancer drug, Keytruda. Additionally, the strong market performance of the drug's new injectable form, Qlex, contributed to the positive financial results.

Timeline

Latest developmentabout 1 hour ago

Merck Raises 2026 Outlook After Quarterly Revenue Reaches $18.1 Billion

Revenue and adjusted earnings topped analysts’ estimates, while the company attributed about $550 million of quarterly growth to drug purchases made earlier than expected.

Read the full story

Key facts

Merck exceeded third-quarter profit and revenue estimates for 2026.
The company raised its full-year adjusted profit outlook driven by strong sales of Keytruda.
The new injectable form of Keytruda, called Qlex, showed strong market performance.